Published • loading... • Updated
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
The regimen cleared a key secondary endpoint, and 79% of treated patients achieved a viral response after 48 weeks, Vir said.
- On October 29, 2026, Gilead Sciences crushed Wall Street's sales expectations, driven by strong performance across its drug portfolio.
- Gilead's financial success was driven primarily by its HIV treatments, which formed the backbone of the company's strong quarterly performance.
- The cancer drug Trodelvy contributed significantly to the reported sales success, complementing the company's infectious disease portfolio.
- By surpassing Wall Street's expectations, Gilead demonstrated robust market positioning and investor confidence in its therapeutic pipeline.
- Historical investment performance does not guarantee future results; prior successes do not ensure continued growth or sustained market outperformance.
Insights by Ground AI
14 Articles
14 Articles
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
Vir Biotechnology (NASDAQ:VIR) said its combination treatment for chronic hepatitis delta met the primary and key secondary endpoints in the pivotal Phase III ECLIPSE 1 trial, with 79% of treated patients achieving undetectable virus at 48 weeks. The company also presented longer-term Phase II data
·Sioux Falls, United States
Read Full Article
Coverage Details
Total News Sources14
Leaning Left0Leaning Right2Center2Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
